After posting an impressive 50% revenue growth in the second quarter, driven by strong patient demand across all three of its core products, this company has confidently raised its full-year revenue guidance. With an upwardly revised full-year guidance and a solid track record of execution, the company is drawing increased investor attention, offering a compelling reason to revisit its stock.
The company we are profiling today is Xeris Biopharma Holdings Inc. (XERS), whose stock touched a new 52-week high of $8.51 last week.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.